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Copyright © 2008 JCBN Summary Endothelin-1, a powerful vasoconstrictor, forms the endothelin system together
with endothelin-converting enzyme and endothelin type A and type B receptors. These
endothelin system components are considered to participate in inflammatory and wound
healing responses. Previous reports have suggested a role for the endothelin-1 in the pathology
of Crohn’s disease. In the present study, we immunohistochemically investigated the
expressions of the endothelin system components in affected human intestinal tissues of
Crohn’s disease. Eighteen surgical specimens of colonic tissue obtained from patients with
Crohn’s disease and 12 normal colonic tissues as controls were examined. Frozen tissue
sections cut from the samples were subjected to the immunohistochemical single and double
staining. The endothelin system components were expressed mainly in the muscular layers and
blood vessels. In diseased colonic tissues, inflammatory infiltration and fibrotic tissue reactions
with marked smooth muscle cell proliferation were frequently seen, and were closely associated
with increased expressions of the endothelin system components. These results strongly suggest
that endothelin-converting enzyme and endothelin type A and type B receptors collectively
play a role in the inflammatory and fibrogenic processes of Crohn’s disease. Especially,
submucosal smooth muscle proliferation, a histological hallmark of strictures, may be
attributable to the upregulated endothelin system.
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Introduction
Crohn’s disease (CD) is an idiopathic inflammatory dis-
order affecting both small and large intestines. Transmural in-
flammation with noncaseating granulomas, and inflammation-
related fibrosis with marked smooth muscle cell (SMC)
proliferation are histological features of this inflammatory
bowel disease, and contribute to the development of its
characteristic complications such as fistulas and strictures
[1, 2]. Despite recent extensive investigations of patients
and through the usage of animal models, the precise
pathological mechanisms of the abnormal inflammatory
responses remain to be elucidated [1, 3].Endothelin System Components and Crohn’s Disease
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Endothelin-1 (ET-1) is a potent vasoconstrictor, and has a
mitogenic effect on SMCs [4, 5]. Because the proliferation
of vascular intimal SMCs is an essential process for
atherogenesis [6, 7], ET-1 has been considered to play a
pathogenic role in the development of atherosclerosis [8, 9].
In addition to atherosclerosis, ET-1 has been considered as a
possible pathological factor in various inflammatory
disorders, including CD [10–13].
ET-1 can be generated locally by the cleavage of its
propeptide, big ET-1, by endothelin-converting enzyme
(ECE) [14]. The biological actions of ET-1 are mediated by
its specific receptors, endothelin type A receptor (ETA) and
endothelin type B receptor (ETB) [15]. Expressions of these
ET system components during inflammatory and wound
healing processes have been reported and its significance on
the disease processes has been investigated [9,  11,  16].
Previous studies demonstrated the increase of ET-1 in sera
and colonic tissues of patients with CD [12, 13]. However,
the expression of ECE in affected intestinal tissues of CD
has not been studied, and the precise roles of ETA and ETB
receptors in the inflammatory and fibrogenic processes of
CD remain to be elucidated.
In the present study, we immunohistochemically investi-
gated the expressions of these ET system components, ECE,
ETA and ETB, in affected human intestinal tissues of CD.
Materials and Methods
Colonic tissue specimens
Eighteen intestinal tissue specimens were sampled from
patients with CD [mean age (yr), 31 ± 6 (±SD); 15 men and
3 women] by surgery. Reasons for the surgical resections
were intestinal strictures (n = 14), fistulas (n = 3) and
abscess (n = 1). Normal colonic tissues as controls were
obtained from 12 patients [mean age (yr), 60 ± 7 (±SD); 9
men and 3 women] having surgery for benign or malignant
colonic tumors. Informed consent was obtained from every
patient, and the Ethics Committee of Osaka City University
Hospital approved this study.
Each colonic tissue specimen was immediately snap-
frozen after sampling and stored at −80°C. The frozen
samples were subsequently sectioned serially at 6-µm
thickness and fixed in acetone. Every first section was
stained with hematoxylin and eosin; the other sections were
used for the following immunohistochemical analysis.
Immunohistochemistry
Single staining—The sources and specificity of all
antibodies used in the present immunohistochemical study
are listed in Table 1. For the analysis of the expressions of
the ET system components in normal and diseased colonic
tissues, we used specific anti-ECE antibody (developed by
one of us), and anti-ETA and anti-ETB antibodies (kindly
provided by Novartis Pharma K.K., Tsukuba Research
Institute, Tsukuba, Japan) as primary antibodies [17, 18].
Sections were incubated with one of these primary anti-
bodies at 4°C overnight or for one hour at room temperature,
and then subjected to a three-step staining procedure using
the streptavidin-biotin complex method. Visualization was
performed by horseradish peroxidase-based colorimetric
reaction with 3-amino-9-ethylcarbazole (10 minutes, room
temperature), and the sections were faintly counterstained
with hematoxylin. The specificity and results obtained with
the primary antibodies were checked by omission of the
antibodies and use of a non-immune mouse IgG antibody
(Dako Cytomation, Glostrup, Denmark) as a negative
control.
Double immunostaining—To identify cell types that
express the ET receptors (ETA and ETB), double immuno-
stainings for ET receptors and SMCs or macrophages were
performed according to the method previously reported with
minor procedural modifications [19]. Alkaline phosphatase
was visualized with fast blue BB (blue: SMC and macro-
phage) and peroxidase with 3-amino-9-ethylcarbazole (red:
ET receptors).
Table 1. Primary antibodies used in the present immunohistochemical study
ECE, endothelin-converting enzyme; ETA, endothelin type A receptor; ETB, endothelin type B receptor; SMC,
smooth muscle cell; Dako, Dako Cytomation (Glostrup, Denmark)
Designation
Clone or  
catalog number
Cell identified Source Dilution
ECE AEC32-236 — Shimada et al. [17] 1:200
ETA — — Sasaki et al. [18] 1:500
ETB — — Sasaki et al. [18] 1:500
α-SMC actin 1A4 SMCs Dako 1:200
CD68 EBM11 Macrophages Dako 1:200
CD31 JC70A Endothelial cells Dako 1:100T. Suekane et al.
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Results
Normal colonic tissues
Normal colonic tissues histologically demonstrated no
fibrotic and no inflammatory changes. Expressions of ECE,
ETA and ETB were seen mainly in the muscular layers and
vasculatures (Fig. 1). Vascular SMCs were positive for ECE,
ETA and ETB (Fig. 2). ETA immunoreactivity in vascular
SMCs was stronger than ETB. Of these ET system compo-
nents, only ECE was detected in endothelial cells (Fig. 2).
Colonic tissues of CD
In diseased intestinal tissues of CD, marked proliferation
and accumulation of SMCs was frequently seen in the
submucosa, in association with inflammatory infiltration
and fibrotic tissue reaction. In addition to original SMC
tissue components including the muscular layers and vessels,
the proliferated SMCs in the submucosa were distinctly
positive for the ET system components, ECE, ETA and ETB
(Fig. 3). In these proliferated SMCs, ETA immunoreactivity
was relatively weak compared to ETB. In contrast, as seen in
normal colonic tissues, expression of ETA in the vascular
SMCs was stronger than that of ETB (Fig. 3). Macrophages
accumulated in the active inflammatory lesions also showed
strong expressions of ECE, ETA, and ETB (Fig. 4). Inflam-
mation associated neovascularization was seen in the
lesions, and the newly formed vessels were invariably
positive for the ET system components (Fig. 4). While ECE
expression was confirmed in the endothelial cells, as well
as the SMCs, of the newly formed vessels, ETB expression
could not be detected in the endothelial cells.
Fig. 1. Expression of the ET system in normal colonic tissue. (A) Immunostaining for SMCs (1A4). (B–D) Immunostaining for ECE
(B), ETA (C) and ETB (D). Main expression sites of these ET system components are muscular layers and vasculatures. Original
magnification: A–D, ×30.Endothelin System Components and Crohn’s Disease
Vol. 42, No. 2, 2008
129
Discussion
This is the first immunohistochemical study based on
frozen human colonic sections, that disclosed enhanced
expressions of the ET system components, ECE, ETA and
ETB, in inflammatory and fibrotic lesions of CD. The finding
strongly suggests that these ET system components are
collectively involved in inflammatory and fibrogenic pro-
cesses of CD.
ET-1 is a vasoconstrictor peptide that contributes not
only to the regulation of vascular tone but also to the repair /
fibrogenic processes after tissue injury [11, 16]. In addition
to cardiovascular system, ET-1 acts on various normal or
diseased organs/tissues [8–13,  16,  20–22]. Inagaki et al.
[21] and Egidy et al. [22] reported the immunolocalization
of ET system components in human normal colonic tissues
and suggested implication of the ET system in physiological
functions of human colons. Moreover, the ET system seems
to be involved in human colonic diseases, including
congenital, neoplastic and inflammatory disorders [12, 13,
23–27]. CD has also been recognized as one of such colonic
diseases, in which the ET system potentially plays a patho-
genic role. In fact, ET-1 levels in both plasma and colonic
tissues were increased in patients with CD compared to
normal subjects [12, 13]. However, no study has revealed
expression patterns of the ET system components other than
ET-1 in human colonic tissues of CD.
ECE is a final key enzyme in the synthesis of ET-1,
and regulates the local ET-1 production [14]. The present
immunohistochemical investigation revealed increased ECE
expression in inflammatory and fibrotic foci in colonic
tissues of patients with CD. The finding can provide a likely
explanation for the results of prior studies that showed
increased ET-1 in CD patients [12,  13]. ECE expression
was observed in accumulated macrophages and in pro-
liferated SMCs, both of which are chief effector cells of
inflammatory and fibrogenic tissue reactions. Hence, up-
regulation of ET-1 production by ECE may be an essential
process in the development and progression of colonic
lesions in CD.
The biological effects of ET-1 are expressed via binding
to its specific receptors, ETA and ETB [ 15]. It had been
recognized that the vasoconstrictive and mitogenic properties
of ET-1 were mediated mainly by ETA [28, 29]. Because
ET-1 binding to ETB stimulates the release of nitric oxide
from endothelial cells, it has been believed that ETB
antagonizes ETA-mediated ET-1 function and therefore
induces vasodilatation [30]. However, accumulating evidence
has recently shown that ETB also contribute to the vaso-
constrictive and mitogenic reactions [11, 16, 31]. We found
that both ETA and ETB expressions were enhanced in
inflamed and fibrotic colonic lesions of CD. Especially in
Fig. 2. Expression of the ET system in a vessel in normal colonic tissue. (A) Immunostaining for endothelial cell marker, CD31. (B–D)
Immunostaining for the ET system components; ECE (B), ETA (C) and ETB (D). Vascular SMCs are positive for all these
ET system components. Of these ET system components, only ECE is detectable in endothelial cells (B; arrow). Original
magnification: A–D, ×400.T. Suekane et al.
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the fibroproliferative foci in the submucosa, ETB was a
dominant ET receptor that was expressed in the proliferated
SMCs. ETB-mediated nitric oxide production from endo-
thelial cells was thought to be absent in the affected colonic
tissues because ETB was not detected in the endothelial
cells. The findings could be interpreted that both ETA- and
ETB-mediated ET-1 actions might contribute to develop the
inflammation-related fibrosis and SMC proliferation, which
is a histological hallmark of intestinal strictures in CD [2].
The precise pathway of the development of CD is still
obscure. The results of the present study suggest at least that
the ET system plays a pathogenic role in the development of
CD and in its characteristic and serious complication,
intestinal strictures. Increased ET-1 in the inflamed colonic
tissues may induce hypercontraction of the muscular layers
and the proliferated SMCs in the submucosa and may
worsen the strictures. These mean potential efficacy of ET
antagonists in prevention of the disease progression and the
complication. Bosentan, a dual ET receptors (ETA and ETB)
blockade [31, 32], may be applicable for the treatment of
CD patients and may introduce favorable outcomes in the
prevention and resolution of intestinal strictures.
Fig. 3. Expression of the ET system in colonic tissues of CD. (A) Immunostaining for SMCs (1A4). Marked SMC proliferation and
accumulation are seen in the submucosa (asterisk). (B–D) Immunostaining for the ET system components; ECE (B), ETA (C)
and ETB (D). In addition to SMCs of the muscular layers and the vessels, the proliferated SMCs in the submucosa are positive
for all these ET system components. ETA immunoreactivity in these proliferated SMCs is relatively weak. (E, F) Double
immunolabeling for ETA (red)/SMC (1A4; blue) (E), and ETB (red)/SMC (1A4; blue) (F). ETA immunoreactivity of the
proliferated SMCs is weaker than ETB immunoreactivity (arrows), and conversely, ETA immunoreactivity of the vascular
SMCs is stronger than that of ETB immunoreactivity (arrowhead). Original magnification: A–D, ×20; E and F, ×100.Endothelin System Components and Crohn’s Disease
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In conclusion, the present study demonstrated the enhanced
expressions of ECE, ETA and ETB in affected human colonic
tissues of CD. These results strongly suggest that the ET
system play a pathogenic role in inflammatory and fibro-
genic processes of CD. Administration of ET antagonist
may improve the prognosis of patients with CD.
Abbreviations
CD, Crohn’s disease; ET-1, endothelin-1; ECE, endo-
thelin-converting enzyme; ETA, endothelin type A receptor;
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